STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount

The stock-based compensation expense related to employees and non-employee directors is reported in the following financial statement line items:


	Years Ended December 31,
	2025		2024		2023
	(In thousands)
Stock-based compensation expense by function:

Selling and marketing expense	$	2,861	$	4,605	$	6,264
General and administrative expense	4,651		24,533		28,386
Product development expense	7,246		5,640		8,764
Total stock-based compensation expense	$	14,758	$	34,778	$	43,414

The expense includes capitalized stock based compensation related to software development costs in the following financial statement line items:


	Years Ended December 31,
	2025		2024		2023
	(In thousands)
Capitalized stock-based compensation expense by function:

Selling and marketing expense	$	—	$	—	$	11
General and administrative expense	1,585		1,432		1,100
Product development expense	4,652		4,412		3,695
Total capitalized stock-based compensation expense	$	6,237	$	5,844	$	4,806

Schedule of Outstanding Unvested Equity Units

Unvested RSUs, MSUs, and PSUs outstanding at December 31, 2025 and changes during the year ended December 31, 2025 are as follows:


	RSUs			MSUs			PSUs
	Number of Shares	Weighted Average Grant Date Fair Value		Number of Shares (a)	Weighted Average Grant Date Fair Value		Number of Shares (a)	Weighted Average Grant Date Fair Value
	(Shares in thousands)
Unvested at January 1, 2025	2,359	$	35.00	291	$	22.90	27	$	104.20
Replacement Awards (b)	114	17.76		—	—		—	—
Granted	2,091	14.48		—	—		—	—
Vested	(1,049)	35.12		(4)	33.58		—	—
Forfeited	(489)	27.15		(7)	25.84		(27)	104.20
Unvested at December 31, 2025	3,026	$	21.40	280	$	22.70	—	$	—

___________________________

(a) Included in the table are MSUs and PSUs which vest in varying amounts depending upon certain market or performance conditions. The MSUs and PSUs in the table above includes these awards at their maximum potential payout.

(b) On March 4, 2025, the Company cancelled equity awards denominated in the shares of one of its international subsidiaries and issued 113,823 RSUs to holders of those awards. There was no incremental cost recognized for these awards as the updated fair value was lower than the original grant date fair value.

Schedule of Changes in Outstanding Stock Options and Stock Appreciation Rights

Stock options and stock appreciation rights outstanding at December 31, 2025 and changes during the year ended December 31, 2025 were as follows:


	December 31, 2025
	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value
	(Shares and intrinsic value in thousands)
Outstanding at January 1, 2025	35	$	102.50
Granted	1,000	15.69
Exercised	—	—
Forfeited	—	—
Expired	(1)	67.61
Outstanding at December 31, 2025	1,034	$	18.57	9.1	$	—
Exercisable	34	$	103.83	1.3	$	—

Schedule of Information for Stock Options and Stock Appreciation Rights Outstanding and Exercisable

The following table summarizes the information about stock options and stock appreciation rights outstanding and exercisable at December 31, 2025:


	Awards Outstanding & Exercisable
Range of Exercise Prices	Outstanding and Exercisable at December 31, 2025	Weighted Average Remaining Contractual Life (In Years)	Weighted Average Exercise Price
	(Shares in thousands)


Greater than $20.00	34	1.3	$	103.83
	34	1.3	$	103.83

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions

The fair value of stock options was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used:


	Year Ended December 31, 2025
Expected volatility	72.15	%
Risk-free interest rate	3.96	%
Expected term	5.33 years
Dividend yield	0.00	%